|
|||||
|
|
The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases |
|
| Affiliation: | 1. Merck & Co., Inc., Kenilworth, NJ, USA;2. MSD Pharma Hungary Kft, Budapest, Hungary |
| Abstract: | |
| Keywords: | Ebola SARS-CoV-2 Vaccines Export Regulations |
| 本文献已被 ScienceDirect 等数据库收录！ | |